Growth hormone cut visceral adiposity, serum cholesterol in HIV patients. (12-Week Results).
To participate in the study, men had to have a waist circumference of more than 88.2 cm, and a waist/hip ratio of more than 0.95. Women had to have a waist circumference of more than 75.3 cm, and a waist/hip ratio of more than 0.9.
Patients were randomized to receive 4 mg of recombinant human growth hormone daily, delivered subcutaneously; 4 mg of growth hormone on alternate days; or placebo. Patients continued to receive anti-HIV treatment and therapies for hyperlipidemia. The year-long study is sponsored by Serono, which makes recombinant human growth hormone.
In an interim, 12-week analysis, changes in visceral adipose tissue were assessed on CT scans in 239 subjects. The 82 patients on daily growth hormone injections lost a mean of 3.3 kg of visceral fat, compared with a mean loss of 1.8 kg among 79 patients who received alternate-day injections, and a mean loss of 0.3 kg among the 78 patients given placebo, said Dr. Kotler, chief of gastroenterology at St. Luke's-Roosevelt Medical Center in New York.
In patients given daily growth hormone injections, total serum cholesterol excluding HDL cholesterol fell from a baseline mean of 178 mg/dL to 157 mg/dL, a statistically significant decline. Patients in the placebo and alternate-day groups had no significant change in cholesterol levels.
The study will next test low-dose maintenance therapy Daily treatment with 4-mg doses of growth hormone would cost more than $1,000 a week based on the drug's average wholesale price.
|Printer friendly Cite/link Email Feedback|
|Author:||Zoler, Mitchel L.|
|Publication:||Internal Medicine News|
|Article Type:||Brief Article|
|Date:||Oct 15, 2002|
|Previous Article:||HAART slashes rate of HIV-related lymphoma. (Survival Time Nearly Doubled).|
|Next Article:||HIV-linked multiple myeloma responds to thalidomide. (No Immunosuppression Seen).|